Epoxyeicosanoids promote organ and tissue regeneration

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 33, 2013, Pages 13528-13533

  Panigrahy, Dipak ^a,b,c,d   Kalish, Brian T ^a   Huang, Sui ^b   Bielenberg, Diane R ^a   Le, Hau D ^a,e   Yang, Jun ^f   Edin, Matthew L ^g   Lee, Craig R ^h   Benny, Ofra ^a   Mudge, Dayna K ^a,b,c,d   Butterfield, Catherine E ^a   Mammoto, Akiko ^a   Mammoto, Tadanori ^a   Inceoglu, Bora ^f   Jenkins, Roger L ⁱ   Simpson, Mary A ⁱ   Akino, Tomoshige ^a   Lih, Fred B ^g   Tomer, Kenneth B ^g   Ingber, Donald E ^a,j   Hammock, Bruce D ^f   Falck, John R ^k   Manthati, Vijaya L ^k   Kaipainen, Arja ^l   D'Amore, Patricia A ^m   Puder, Mark ^a   Zeldin, Darryl C ^g   Kieran, Mark W ^a,b   more..

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Center for Lung Biology   (United States)

^d Institute for Systems Biology ^*  (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^h UNC Hamner Institute for Drug Safety Sciences   (United States)

ⁱ LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^j HARVARD UNIVERSITY   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l USA   (United States)

^m SCHEPENS EYE RESEARCH INSTITUTE   (United States)

more..

Author keywords

Angiocrine; Autacoid; Organ regeneration; Small molecule mediator; VEGF

Indexed keywords

AUTACOID; CYTOCHROME P450 2C8; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; KIDNEY DEVELOPMENT; LIVER CELL; LIVER REGENERATION; LUNG DEVELOPMENT; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RETINA BLOOD VESSEL; TISSUE GROWTH; TISSUE REGENERATION; WOUND HEALING;

ANGIOCRINE; AUTACOID; ORGAN REGENERATION; SMALL MOLECULE MEDIATOR; VEGF;

ANIMALS; CHROMATOGRAPHY, LIQUID; EICOSANOIDS; ENDOTHELIAL CELLS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; EYE; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; LUNG; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, TIE-2; REGENERATION; TANDEM MASS SPECTROMETRY;

EID: 84882380783     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311565110     Document Type: Article

References (47)

1. Gronert K (2008) Lipid autacoids in inflammation and injury responses: A matter of privilege. Mol Interv 8(1):28-35.
2. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276(39):36059-36062.
3. Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8(10):794-805.
4. Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC (2011) EET signaling in cancer. Cancer Metastasis Rev 30(3-4):525-540.
5. Greene ER, Huang S, Serhan CN, Panigrahy D (2011) Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 96(1-4):27-36.
6. Goessling W, et al. (2009) Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136(6):1136-1147.
7. Gronert K, et al. (2005) A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 280(15):15267-15278.
8. Fleming I (2008) Vascular cytochrome p450 enzymes: Physiology and pathophysiology. Trends Cardiovasc Med 18(1):20-25.
9. Rupnick MA, et al. (2002) Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 99(16):10730-10735.
10. Street J, et al. (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99(15):9656-9661.
11. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273-286.
12. Kaspera R, Totah RA (2009) Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol 5(7):757-771.
13. Fife KL, et al. (2008) Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther 327(3):707-715.
14. Ding BS, et al. (2010) Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468(7321):310-315.
15. Ding BS, et al. (2011) Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147(3):539-553.
16. Abdu E, et al. (2011) Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures. J Neurochem 117(4):632-642.
17. Luria A, et al. (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA 108(22):9038-9043.
18. Sander AL, et al. (2011) Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model. Langenbecks Arch Surg 396(8):1245-1253.
19. Lee CR, et al. (2010) Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 24(10):3770-3781.
20. Panigrahy D, et al. (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122(1):178-191.
21. Seubert JM, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99(4):442-450.
22. Edin ML, et al. (2011) Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 25(10):3436-3447.
23. Webler AC, et al. (2008) Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 295(5): C1292-C1301.
24. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50(16):3825-3840.
25. Tsai HJ, et al. (2010) Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci 40(3):222-238.
26. Gauthier KM, et al. (2002) 14,15-Epoxyeicosa-5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90(9):1028-1036.
27. Li X, Claesson-Welsh L, Shibuya M (2008) VEGF receptor signal transduction. Methods Enzymol 443:261-284.
28. Adini A, et al. (2009) Matrigel cytometry: A novel method for quantifying angiogenesis in vivo. J Immunol Methods 342(1-2):78-81.
29. Panigrahy D, et al. (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110(7):923-932.
30. Pozzi A, et al. (2005) Characterization of 5,6-and 8,9- epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280(29):27138-27146.
31. Bao P, et al. (2009) The role of vascular endothelial growth factor in wound healing. J Surg Res 153(2):347-358.
32. D'Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35(12):3974-3979.
33. Greene AK, et al. (2003) Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 237(4):530-535.
34. Drixler TA, et al. (2002) Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 236(6):703-711, discussion 711-712.
35. LeCouter J, et al. (2003) Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. Science 299(5608):890-893.
36. Tassi E, et al. (2011) Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol 179(5):2220-2232.
37. Song JJ, Ott HC (2011) Organ engineering based on decellularized matrix scaffolds. Trends Mol Med 17(8):424-432.
38. Simpson DG (2006) Dermal templates and the wound-healing paradigm: The promise of tissue regeneration. Expert Rev Med Devices 3(4):471-484.
39. Dogrul AB, et al. (2010) Antiangiogenic response after 70% hepatectomy and its relationship with hepatic regeneration and angiogenesis in rats. Surgery 147(2): 288-294.
40. Sakurai MK, et al. (2007) Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol 292(3):L742-L747.
41. Galambos C, et al. (2002) Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. Am J Respir Cell Mol Biol 27(2):194-203.
42. Harari-Steinberg O, Pleniceanu O, Dekel B (2011) Selecting the optimal cell for kidney regeneration: Fetal, adult or reprogrammed stem cells. Organogenesis 7(2):123-134.
43. Lau TT, Wang DA (2011) Stromal cell-derived factor-1 (SDF-1): Homing factor for engineered regenerative medicine. Expert Opin Biol Ther 11(2):189-197.
44. Vanella L, et al. (2011) Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes. Prostaglandins Other Lipid Mediat 96(1-4):54-62.
45. Sakurai MK, Greene AK, Wilson J, Fauza D, Puder M (2005) Pneumonectomy in the mouse: Technique and perioperative management. J Invest Surg 18(4):201-205.
46. Kaipainen A, et al. (2007) PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2(2):e260.
47. Panigrahy D, et al. (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 105(3): 985-990.